title: IVIG for the treatment of toxic epidermal necrolysis.
abstract: Intravenous immunoglobulin (IVIG) has been proposed as a treatment for toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). A number of retrospective and prospective studies have been conducted, with varying levels of evidence for the efficacy of IVIG. Recent publications provide opposing conclusions. A multi-center, comparative, long-term analysis needs to be conducted to determine the role of IVIG in the management of patients with SJS/TEN.
authors.affiliation: Division of Clinical Pharmacology, University of Toronto, Ontario, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Mittmann
authors.forename: B C
authors.initials: BC
authors.lastname: Chan
authors.forename: S
authors.initials: S
authors.lastname: Knowles
authors.forename: N H
authors.initials: NH
authors.lastname: Shear
mesh_terms: D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy*
chemical_list: D016756:Immunoglobulins, Intravenous